Profile data is unavailable for this security.
About the company
Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.
- Revenue in INR (TTM)4.20bn
- Net income in INR529.90m
- Incorporated1969
- Employees1.54k
- LocationThemis Medicare Ltd11/12 Udyog Nagar, S V Road, Goregaon (West)MUMBAI 400104IndiaIND
- Phone+91 2 267607080
- Fax+91 2 228746621
- Websitehttps://www.themismedicare.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sigachi Industries Ltd | 4.36bn | 660.99m | 15.91bn | 991.00 | 28.30 | 3.37 | 20.46 | 3.65 | 1.69 | 1.69 | 11.11 | 14.15 | 0.6266 | 3.01 | 3.27 | 4,396,491.00 | 9.36 | 14.77 | 13.25 | 19.57 | 50.50 | 50.30 | 14.93 | 14.92 | 1.39 | 6.47 | 0.2576 | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| JG Chemicals Ltd | 7.57bn | 550.05m | 17.03bn | 56.00 | 29.43 | 3.90 | 27.30 | 2.25 | 14.77 | 14.77 | 202.34 | 111.33 | -- | -- | -- | 135,230,700.00 | -- | -- | -- | -- | 17.29 | -- | 7.56 | -- | 11.46 | -- | 0.0281 | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Syncom Formulations (India) Ltd | 3.29bn | 331.47m | 18.58bn | 802.00 | 48.70 | 5.93 | 48.28 | 5.64 | 0.406 | 0.406 | 3.49 | 3.34 | 0.8485 | 6.21 | 3.62 | 4,105,761.00 | 8.54 | 7.50 | 10.99 | 10.23 | 38.49 | 34.10 | 10.07 | 9.38 | 4.09 | 12.05 | 0.0435 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Beta Drugs Ltd | 3.35bn | 410.00m | 19.06bn | 371.00 | 46.50 | 10.54 | 37.34 | 5.70 | 42.65 | 42.65 | 348.21 | 188.13 | 1.26 | 4.04 | 3.74 | 9,022,873.00 | 15.42 | 15.10 | 23.35 | 22.23 | 39.95 | 39.77 | 12.25 | 12.38 | 1.59 | 17.06 | 0.0953 | 0.00 | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
| Windlas Biotech Ltd | 6.96bn | 612.28m | 19.37bn | 1.15k | 31.73 | 4.11 | 23.95 | 2.78 | 29.20 | 29.20 | 331.88 | 225.63 | 1.06 | 6.07 | 4.43 | 6,028,180.00 | 9.30 | -- | 13.64 | -- | 37.52 | -- | 8.80 | -- | 1.61 | 30.61 | 0.0388 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 20.06bn | 2.78k | 16.92 | -- | 10.85 | 0.9683 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| SMS Pharmaceuticals Ltd | 7.68bn | 593.38m | 20.26bn | 1.20k | 34.05 | 3.59 | 22.14 | 2.64 | 7.03 | 7.03 | 91.03 | 66.57 | 0.7278 | 1.81 | 4.18 | 6,420,048.00 | 5.55 | 5.43 | 8.40 | 7.33 | 30.10 | 33.30 | 7.62 | 7.87 | 0.7104 | 4.54 | 0.3361 | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Hester Biosciences Ltd | 3.12bn | 234.69m | 20.26bn | 642.00 | 83.96 | 6.71 | 48.11 | 6.49 | 28.37 | 28.37 | 368.62 | 354.81 | 0.4617 | 1.22 | 3.23 | 4,862,882.00 | 3.89 | 6.15 | 4.91 | 7.69 | 71.13 | 66.64 | 8.42 | 12.83 | 1.22 | 2.85 | 0.4371 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| Amrutanjan Health Care Ltd | 4.38bn | 475.20m | 20.39bn | 635.00 | 42.95 | 6.85 | 37.85 | 4.66 | 16.43 | 16.43 | 151.37 | 103.00 | 1.19 | 6.89 | 12.85 | 6,893,025.00 | 12.88 | 16.22 | 16.48 | 20.12 | 50.03 | 53.09 | 10.86 | 13.23 | 3.62 | 217.88 | 0.0074 | 18.95 | 10.96 | 10.71 | 12.90 | 12.46 | 26.93 | 16.43 |
| Panacea Biotec Ltd | 5.50bn | -148.63m | 25.36bn | 1.15k | -- | 3.04 | 127.01 | 4.61 | -2.46 | -2.46 | 90.20 | 135.98 | 0.4374 | 1.10 | 7.87 | 4,799,546.00 | -1.22 | 10.26 | -1.65 | 16.53 | 63.28 | 50.27 | -2.79 | 24.87 | 1.03 | -13.78 | 0.0254 | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Themis Medicare Ltd | 4.20bn | 529.90m | 26.48bn | 1.54k | 50.02 | 6.43 | 41.38 | 6.30 | 5.75 | 5.75 | 45.63 | 44.76 | 0.7306 | 2.39 | 2.22 | 2,727,670.00 | 9.21 | 11.12 | 12.57 | 16.46 | 64.64 | 60.32 | 12.61 | 14.96 | 1.56 | -- | 0.1651 | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| Indoco Remedies Ltd | 17.73bn | 320.40m | 27.63bn | 5.93k | 89.86 | 2.54 | 20.27 | 1.56 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| RPG Life Sciences Limited | 6.18bn | 706.60m | 33.61bn | 1.27k | 47.57 | 8.86 | 37.39 | 5.44 | 42.72 | 42.72 | 373.86 | 229.38 | 1.22 | 1.99 | 8.44 | 4,868,662.00 | 13.92 | 16.07 | 19.35 | 21.77 | 67.85 | 62.99 | 11.43 | 11.99 | 1.45 | 207.32 | 0.00 | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Dishman Carbogen Amcis Ltd | 26.19bn | -1.74bn | 34.26bn | 1.13k | -- | 0.5972 | 38.80 | 1.31 | -11.09 | -11.09 | 166.94 | 365.90 | 0.2661 | 0.6339 | 4.45 | 23,132,690.00 | -1.77 | -0.3986 | -2.21 | -0.4888 | 78.75 | 73.83 | -6.65 | -1.54 | 0.6001 | -0.0583 | 0.3041 | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
Data as of Nov 22 2024. Currency figures normalised to Themis Medicare Ltd's reporting currency: Indian Rupee INR
0.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 37.42k | 0.04% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 1.65k | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 652.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Oct 2024 | 402.00 | 0.00% |
| DFA Australia Ltd.as of 30 Sep 2024 | 134.00 | 0.00% |
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
